A clinical trial to study the effects of alternate day fasting and the 5:2 diet on adults with overweight and obesity.

Phase 4

Conditions: Health Condition 1: E66- Overweight and obesity

Registration Number: CTRI/2024/07/070656

Lead Sponsor: Maulana Azad Medical College and Associated Hospitals

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Open to Recruitment

Sex: Not specified

Target Recruitment: 0

Inclusion Criteria

1.Body Mass Index equals or greater than 23 kilograms per square meter (as per WHO Asian BMI classification),

2.Able to give informed consent,

3.Not planning to relocate within 6 months of the study,

4.Willing to participate in this weight loss intervention.

Exclusion Criteria

1.Individuals suffering from disorders like Celiac disease, uncontrolled thyroid disorder, anorexia bulimia.

2.Individuals with comorbid conditions in which dietary restrictions will be detrimental like individuals with Stroke, Cardiomyopathy, Coronary artery disease, other Cardio-vascular disease, Chronic Obstructive Pulmonary Disease, Alzheimers disease, Depression.

3.Individuals who have previous weight loss surgery, moderate or severe chronic hepatorenal diseases or cardio-cerebrovascular diseases, current acute complications of diabetes, such as diabetic ketosis, hyperglycaemia and hypertonicity in the past 3 months, stress diseases such as surgery, trauma, and cardiovascular and cerebrovascular events, and mental disorders requiring antipsychotic drugs.

4.Women who are lactating, pregnant or planning for pregnancy.

5.Individuals undergoing some weight loss intervention or have undergone weight loss intervention within 3 months tim

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in body weight, body mass indexTimepoint: At Baseline 0 week <br/ ><br>At Midline 6 weeks <br/ ><br>At Endline 12 weeks

Secondary Outcome Measures

Name	Time	Method
ipid levels, Fasting Blood Glucose, HbA1C, HOMA IR, Fasting insulin, Ferritin, IL-6, Adiponectin, Total energy intake. Improvement in quality of life and parameters like physical, emotional and social well-beingTimepoint: At Baseline 0 week <br/ ><br>At Endline 12 weeks;reduction in body fat, visceral fat, improvement in waist to hip ratioTimepoint: At Baseline 0 week <br/ ><br>At Midline 6 weeks <br/ ><br>At Endline 12weeks